Patents by Inventor Steven Robert Miller

Steven Robert Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
    Patent number: 6548499
    Abstract: Quinoxaline compounds are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as interleukin-8 (IL-8) receptor antagonists and can be used in the treatment of a chemokine-mediated disease wherein the chemokine binds to an IL-8a (CXCR1) or b (CXCR2) receptor such as a chemokine-mediated disease selected from psoriasis, or atopic distress syndrome, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, gastric ulcer, septic shock, endotoxic shock, gram-negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephritis, or thrombosis, Alzheimer's disease, graft versus host reaction, allograft rejections, or allergic diseases.
    Type: Grant
    Filed: October 20, 2000
    Date of Patent: April 15, 2003
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Kenneth G. Carson, David Thomas Connor, Jie Jack Li, Joseph Edwin Low, Jay R. Luly, Steven Robert Miller, Bruce David Roth, Bharat Kalidas Trivedi
  • Chemokine receptor antagonists
    Publication number: 20020072606
    Abstract: The instant invention is a series of compounds which are MCP-1 receptor antagonists of Formula I 1
    Type: Application
    Filed: July 5, 2001
    Publication date: June 13, 2002
    Applicant: Warner-Lambert Company
    Inventors: Larry Don Bratton, Steven Robert Miller, Bruce David Roth, Bharat Kalidas Trivedi, Paul Charles Unangst
  • Chemokine receptor antagonists
    Patent number: 6316449
    Abstract: The instant invention is a series of compounds which are MCP-1 receptor antagonists of Formula I Also included in the invention are intermediates and processes for the preparation of the compounds as well as methods of using the compounds as agents for the treatment of atherosclerosis, chronic and acute inflammatory disease, chronic and acute immune disorders and transplant rejection as well as for preventing infection by HIV, treating infection by HIV, delaying the onset of AIDS, or treating AIDS.
    Type: Grant
    Filed: April 25, 2000
    Date of Patent: November 13, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Larry Don Bratton, Steven Robert Miller, Bruce David Roth, Bharat Kalidas Trivedi, Paul Charles Unangst
  • Method of treating psychosis and schizophrenia
    Patent number: 6051605
    Abstract: This invention relates to compounds that are antagonists of dopamine D4 receptors, and to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors.
    Type: Grant
    Filed: January 29, 1999
    Date of Patent: April 18, 2000
    Assignee: Warner-Lambert Company
    Inventors: Thomas Capiris, David Thomas Connor, Steven Robert Miller, Paul Charles Unangst, Lawrence David Wise
  • Compounds and method of treating psychosis and schizophrenia
    Patent number: 6020364
    Abstract: This invention relates to compounds that are antagonists of dopamine D4 receptors, and to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors.
    Type: Grant
    Filed: February 22, 1999
    Date of Patent: February 1, 2000
    Assignee: Warner-Lambert Company
    Inventors: David Thomas Connor, Stephen Joseph Johnson, Suzanne Ross Kesten, Steven Robert Miller, Paul Charles Unangst, Lawrence David Wise
  • Compounds and method of treating psychosis and schizophrenia
    Patent number: 5916914
    Abstract: This invention relates to compounds that are antagonists of dopamine D4 receptors, and to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors.
    Type: Grant
    Filed: August 8, 1997
    Date of Patent: June 29, 1999
    Assignee: Warner-Lambert Company
    Inventors: David Thomas Connor, Stephen Joseph Johnson, Suzanne Ross Kesten, Steven Robert Miller, Paul Charles Unangst, Lawrence David Wise
  • Antipsychotic method utilizing certain tetrahydrochromeno?3,4-c!pyridin-5-ones
    Patent number: 5760050
    Abstract: 1,2,3,4-Tetrahydro-chromeno?3,4-c!pyridin-5-ones of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, and R.sub.5 include hydrogen, alkyl, alkoxy, hydroxy, halo, nitro, amino, and trifluoromethyl; R.sub.4 is unsubstituted or substituted phenyl, pyridyl, or quinolinyl; and n is 0 to 4, are useful to treat psychosis in mammals, particularly schizophrenia.
    Type: Grant
    Filed: February 27, 1997
    Date of Patent: June 2, 1998
    Assignee: Warner-Lambert Company
    Inventors: David Thomas Connor, Steven Robert Miller, Paul Charles Unangst, Lawrence David Wise